Merck & Co., Inc.
MRK.N
LATEST TRADE
76.61USD
CHANGE
-0.62(-0.80%)
VOLUME
8,589,423
TODAY'S RANGE
76.16 - 77.22
52 WEEK RANGE
71.72 - 87.79
As of 1:02 PM PDT Jun 18 on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close76.61
Open--
Volume--
3M AVG Volume247.76
Today's High--
Today's Low--
52 Week High87.79
52 Week Low71.72
Shares Out (MIL)2,532.06
Market Cap (MIL)193,981.00
Forward P/E12.54
Dividend (Yield %)3.39
6/18/2021
$76.61
MRK.N
76.61
Advanced Charting
Next Event
Merck & Co Inc at Guggenheim Biopharma's Next Decade Virtual ConferenceJun 22, 2021
Latest Developments
More
4 days ago
MSD Announces Supply Agreement With U.S. Government For Molnupiravir, An Investigational Oral Antiviral Candidate For Treatment Of Mild To Moderate Covid-19
6 days ago
Linnaeus Therapeutics Announced Expansion Of Ongoing Clinical Collaboration With Merck
12 days ago
Merck Announces Supply Agreement With U.S. Government For Molnupiravir, An Investigational Oral Antiviral Candidate For Treatment Of Mild To Moderate Covid-19
About Merck & Co., Inc.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.
INDUSTRY
Biotechnology & Drugs
CONTACT INFO
2000 Galloping Hill Rd
KENILWORTH, NJ
07033-1310
United States
+1.908.7404000
http://www.merck.com/
EXECUTIVE LEADERSHIP
Kenneth C. Frazier
Chairman of the Board, Chief Executive Officer
Robert M. Davis
President
Caroline Litchfield
Chief Financial Officer, Executive Vice President
Franklin K. Clyburn
President, Human Health, Head of Human Health Commercial and Marketing
Dean Y. Li
President - Merck Research Laboratories
Key Stats
2.08 mean rating - 26 analysts
SELLHOLDBUY
REVENUE (MM, USD)
2018
42.3K
2019
46.8K
2020
48.0K
2021(E)
48.4K
EPS (USD)
2018
4.340
2019
5.190
2020
5.940
2021(E)
6.109
Price To Earnings (TTM)27.70
Price To Sales (TTM)4.04
Price To Book (MRQ)7.20
Price To Cash Flow (TTM)17.99
Total Debt To Equity (MRQ)115.99
LT Debt To Equity (MRQ)89.08
Return On Investment (TTM)11.21
Return On Equity (TTM)8.02
Latest News
U.S. signs $1.2 billion deal for 1.7 million courses of Merck's experimental COVID-19 drug
Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.
12 days ago
Merck says U.S. govt to buy about 1.7 mln courses of co's COVID-19 drug
Merck & Co Inc said on Wednesday the U.S. government has agreed to buy about 1.7 million courses of the company's experimental COVID-19 drug, molnupiravir, for about $1.2 billion, if it is authorized in the country. (Reporting by Manojna Maddipatla in Bengaluru; Editing...
13 days ago
AstraZeneca's Lynparza reduces relapse, death in breast cancer patients
AstraZeneca Plc's drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday.
17 days ago
Germany's Merck sees boost from labs supplies earnings
Germany's Merck on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.
a month ago
German labs supplier Merck raises forecast on strong first quarter
German biotech labs supplier Merck raised its 2021 earnings forecast on strong first-quarter results, as efforts by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its products.
2 months ago
Congo declares end of Ebola outbreak that killed six
The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.
2 months ago
Congo declares end of Ebola outbreak that killed six
The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.
2 months ago
U.S. drugmaker Merck sees bigger hit to full-year sales from pandemic
Merck & Co Inc said on Thursday it would take a bigger hit to sales this year than previously expected due to a resurgence in COVID-19 cases that has hurt demand for drugs that need to be given by doctors.
2 months ago
BRIEF-Merck Says Not Extending Trial For COVID-19 Drug Molnupiravir Into India At This Time
* MERCK & CO EXEC SAYS Q1 VACCINE SALES HURT BY RECOMMENDATIONS AGAINST CO-ADMINISTRATION OF COVID-19 VACCINES WITH OTHER SHOTS
2 months ago
Merck quarterly profit falls on COVID-19 hit
Merck & Co Inc reported a 1% fall in quarterly profit on Thursday, hurt by a drop in visits to the doctor's office because of a resurgence in COVID-19 cases at the beginning of the year in the United States. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila...
2 months ago
Merck taps five Indian drugmakers to expand COVID-19 drug production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
2 months ago
Merck taps 5 Indian drugmakers to expand COVID-19 drug production
Merck & Co Inc said on Tuesday it had tied up with five generic drugmakers in India to expand access to molnupiravir, an experimental antiviral COVID-19 therapy it is developing with Ridgeback Biotherapeutics. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan...
2 months ago
Merck plans large outpatient trial of COVID-19 pill, stops study in hospitalized patients
Merck & Co Inc on Thursday said it plans a large study of what could become the first pill to target the coronavirus in people at risk of severe COVID-19, but will no longer pursue use of the experimental antiviral drug in hospitalized patients.
3 months ago
WHO joins Europe, Merck in recommending against ivermectin for COVID-19
The World Health Organization (WHO) on Wednesday recommended against using generic anti-parasite drug ivermectin in patients with COVID-19 except for clinical trials, because of a lack of data demonstrating its benefits.
3 months ago
Merck names Caroline Litchfield as new CFO
Merck & Co Inc said on Wednesday Caroline Litchfield will succeed Robert Davis as the company's chief financial officer from April 1.
3 months ago
UPDATE 1-EU regulator warns against use of Merck's anti-parasite drug for COVID-19
Europe's drugs regulator on Monday warned against the use of Merck & Co's anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.
3 months ago
EU regulator advises against use of Merck's anti-parasite drug for COVID-19
The European medicines regulator on Monday advised against the use of Merck & Co's anti-parasite drug, ivermectin, for the treatment or prevention of COVID-19 outside clinical trials.
3 months ago
Merck's marketing executive Michael Nally to step down
Merck & Co said on Wednesday its Chief Marketing Officer Michael Nally will leave the company, the second top executive to do so after the drugmaker announced last month its Chief Executive Officer Kenneth Frazier will step down in June.
4 months ago
Gilead, Merck collaborate to develop long-acting HIV treatment
Gilead Sciences Inc and rival Merck & Co Inc said on Monday they will test a combination of their experimental HIV drugs to develop a long-acting treatment for the infection that affects millions worldwide.
4 months ago
Gilead, Merck collaborate to develop HIV treatment - WSJ
Drug makers Gilead Sciences Inc and Merck & Co Inc are collaborating to develop a long-acting HIV therapy, the Wall Street Journal reported on Monday. (Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)
4 months ago
Biden says Americans will be first to get vaccines; any surplus to be shared
The U.S. government will first give Americans COVID-19 vaccines, but any surplus would be shared with the world, President Joe Biden said on Wednesday after earlier announcing plans to procure an additional 100 million doses.
4 months ago
Judge shuts down MDL claiming link between diabetes drugs and pancreatic cancer
A federal judge in San Diego has rejected claims by some 1,500 plaintiffs in a multidistrict litigation that several similar type 2 diabetes drugs increase the risk of pancreatic cancer.
4 months ago
Idorsia insomnia drug starts FDA review as founder Clozel's second act proceeds
Idorsia's insomnia drug was accepted for review by U.S. regulators, the Swiss drugmaker said on Wednesday, as founder Jean-Paul Clozel edges closer to bringing his new company's first drug to market since selling Actelion for $30 billion.
4 months ago
COVID SCIENCE-Vaccine response may be weaker in elderly; Merck drug shows promise in reducing virus level
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
4 months ago
Biden to meet on with CEOs of JNJ, Merck at White House on Wednesday: official
U.S. President Biden will meet with the chief executives of Johnson & Johnson and Merck & Co Inc at the White House on Wednesday after the companies recently announced a COVID-19 vaccine manufacturing deal, a White House official said on Monday.
4 months ago
Merck says study shows COVID-19 drug causes quick reduction in virus
U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19.
4 months ago
U.S. will invest $100 million to help J&J and Merck vaccine partnership
The White House said the federal government in planning to spend $100 million to help the recently announced vaccine partnership between Merck & Co and rival Johnson & Johnson, White House senior adviser Andy Slavitt said on Wednesday.
4 months ago
Biden calls on states to prioritize vaccinations for teachers
President Joe Biden on Tuesday called on U.S. states to prioritize COVID-19 vaccinations for teachers to ensure children could return to school quickly and safely, and said every educator should receive at least one shot by the end of March.
4 months ago
Biden says will have enough COVID-19 vaccine for every U.S. adult by May
The United States will have enough COVID-19 vaccine for every American adult by the end of May, President Joe Biden said on Tuesday after Merck & Co agreed to make rival Johnson & Johnson's inoculation.
4 months ago
White House using Defense Production Act to equip Merck plants for Johnson & Johnson vaccine
The United States is using the Defense Production Act to equip drugmaker Merck & Co's plants to make Johnson & Johnson's just approved COVID-19 vaccine, White House press secretary Jen Psaki said on Tuesday.
4 months ago
Merck to help make Johnson & Johnson's vaccine - Washington Post
Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine, the Washington Post reported on Tuesday, citing senior officials from U.S. President Joe Biden's administration.
4 months ago
BRIEF-Merck Will Help Make Johnson & Johnson Coronavirus Vaccine - Washington Post
* MERCK WILL HELP MAKE JOHNSON & JOHNSON CORONAVIRUS VACCINE - WASHINGTON POST
4 months ago
Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug
Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer.
4 months ago
UPDATE 1-Merck says FDA requires more data on its COVID-19 drug
Merck & Co said on Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.
4 months ago
Merck says FDA requires more data on its COVID-19 drug
Merck & Co said on Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.
4 months ago
Merck to buy drug developer Pandion Therapeutics for $1.85 billion
Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for about $1.85 billion in cash, to expand its portfolio of drugs that target autoimmune diseases.
4 months ago
Merck to buy drug developer Pandion Therapeutics for $1.85 bln
Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for $1.85 billion, to expand its portfolio of drugs that target autoimmune diseases. (Reporting by Manas Mishra in Bengaluru; Editing by Ramakrishnan M.)
4 months ago
Merck in talks with governments, other drugmakers to produce COVID-19 shots (Feb. 10)
(In Feb 10 story, corrects paragraph 8 to show Themis is an Austrian drugmaker, not Australian)
5 months ago
Merck in talks to possibly produce COVID-19 shots - WSJ
Merck & Co Inc is in talks with governments and companies to potentially help with manufacturing COVID-19 vaccines that have been already authorized, the Wall Street Journal reported on Wednesday.
5 months ago
One of the few top U.S. Black CEOs, Merck's Ken Frazier to retire
Merck & Co Inc said on Thursday Ken Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis.
4 months ago
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.
Apps​Newsletters​Advertise with UsAdvertising Guidelines​Cookies​Terms of UsePrivacyDo Not Sell My Personal Information
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All Rights Reserved.